| Drug Name |
Flumazenil |
| Drug ID |
BADD_D00919 |
| Description |
Fumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system. |
| Indications and Usage |
For the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, and where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures. Also for the management of benzodiazepine overdose as an adjunct for appropriate supportive and symptomatic measures. |
| Marketing Status |
approved |
| ATC Code |
V03AB25 |
| DrugBank ID |
DB01205
|
| KEGG ID |
D00697
|
| MeSH ID |
D005442
|
| PubChem ID |
3373
|
| TTD Drug ID |
D0D5GD
|
| NDC Product Code |
51916-311; 0404-9860; 71872-7008; 14778-0101; 36000-148; 0143-9784; 51662-1254; 0404-9859; 70518-3456; 58175-0365; 0143-9783; 51662-1579; 52584-088; 65129-2026; 36000-149; 0143-9684; 52584-089; 51662-1253; 63323-424; 71872-7038; 71872-7206; 0143-9683 |
| UNII |
40P7XK9392
|
| Synonyms |
Flumazenil | Flumazepil | Romazicon | Lanexat | Ro 15-1788 | Ro 15 1788 | Ro 151788 | Anexate |
